PCSK9 - new perspectives for lipid-lowering pharmacotherapy in patients with coronary artery disease
Optimal hypolipemic therapy reduces the risk of cardiovascular death. The drugs used in Poland are: statins, ion exchange resins, cholesterol absorption inhibitors, fibrates and proprotein subtylsin/cexin type 9 converting enzyme inhibitors (PCSK9). The function of PCSK9 is to bind receptors for LDL...
Saved in:
Main Authors: | Natalia Pauli (Author), Monika Rac (Author) |
---|---|
Format: | Book |
Published: |
Polish Pharmaceutical Society,
2020-07-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Lipid-lowering interventions targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): an emerging chapter in lipid-lowering therapy
by: Constantine E Kosmas, et al.
Published: (2017) -
Association between Plasma PCSK9 levels and Presence of Coronary Artery Calcium
by: Tahir Mahmood, et al.
Published: (2020) -
PCSK9 INHIBITORS IN PERIPHERAL ARTERY DISEASE: REVIEW OF EFFICACY, SAFETY, AND OUTCOMES
by: Moiud Mohyeldin
Published: (2024) -
The wind of change - PCSK9 inhibitors in hypolipidemic treatment. The Polish perspective
by: Natalia Ilnicka, et al.
Published: (2023) -
PCSK9 Inhibitors in Clinical Practice: Experience of a Specialized Lipid Center
by: A. V. Blokhina, et al.
Published: (2022)